Tumor-associated necrotic DNA

Tumor-associated necrotic DNA consists of genomic material and associated histone proteins that are exposed to the extracellular environment following the necrotic death of cancer cells within solid tumors [1]. In healthy, viable tissues, these components are sequestered within the nucleus and are inaccessible to circulating antibodies; however, the rapid, disordered growth of solid tumors often results in hypoxic regions and subsequent necrosis, where cell membrane integrity is compromised [2]. This creates a unique and abundant target for 'inside-out' therapeutic strategies, as the exposed DNA serves as a stable antigen that is not present in healthy, non-necrotic tissues [3]. Therapeutic agents, such as the Tumor Necrosis Treatment (TNT) series of monoclonal antibodies, are designed to bind specifically to these exposed nucleic acids to deliver cytotoxic payloads [4]. By targeting the necrotic core, these drugs can deliver concentrated doses of radioactive isotopes (e.g., Iodine-131) or pro-inflammatory cytokines (e.g., IL-2) directly into the tumor mass, thereby treating the surrounding viable malignant cells while minimizing damage to healthy organs [5]. Citations: [1] Chen, S., et al. (2014). World Journal of Radiology. [2] Epstein, A. L., et al. (1988). Cancer Research. [3] King, S. W., et al. (2004). Frontiers in Bioscience. [4] Street, N. W., et al. (2006). Cancer Biotherapy & Radiopharmaceuticals. [5] Bosslet, K., et al. (1998). British Journal of Cancer.

Other names

Necrotic DNADNA-histone complexIntracellular DNA-associated antigensTumor necrotic core DNAExposed genomic DNA

Antibodies bind to DNA or DNA-histone complexes that become accessible only in necrotic cells due to the loss of cell membrane integrity, allowing for the localized delivery of radionuclides or immunomodulatory cytokines to the tumor microenvironment.